Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: No evidence of increased risk of leukemia development

Bone Marrow Transplantation

Volumn 30, Issue 10, 2002, Pages 661-663

  Anderlini, P ^a   Chan, F A ^a   Champlin, R E ^a   Korbling M ^a   Strom, S S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Allogeneic peripheral blood progenitor cell transplantation; Filgrastim; Leukapheresis; Normal donors; rhG CSF

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHILD; CONTROLLED STUDY; DISEASE COURSE; DONOR; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH SURVEY; HEMATOPOIETIC STEM CELL; HUMAN; INTERVIEW; LEUKEMIA; LEUKEMOGENESIS; MALE; PRIORITY JOURNAL; SAMPLE SIZE; CHEMICALLY INDUCED DISORDER; COOPERATION; INFORMATION PROCESSING; METHODOLOGY; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; AGED; CHILD; COOPERATIVE BEHAVIOR; DATA COLLECTION; FEMALE; FILGRASTIM; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK ASSESSMENT; TISSUE DONORS;

EID: 0036862151     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703693     Document Type: Article

References (11)

1. Russell N, Gratwohl A, Schmitz N. Developments in allogeneic peripheral blood progenitor cell transplantation. Br J Haematol 1998; 103: 594-600.
2. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-1415.
3. Fischer J, Frick M, Kiesel U et al. Primary unrelated allografting with G-CSF mobilized PBPC: experience with 100 donations out of one single institution. Blood 1998; 92: 723a (Abstr.).
4. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78: 2791-2808.
5. Cavallaro AM, Lilleby K, Majolino I et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85-89.
6. Stroncek D, Clay ME, Herr G et al. Blood counts in healthy donors one year following the collection of G-CSF mobilized stem cells and the results of a second mobilization and collection. Transfusion 1997; 37: 304-308.
7. Storek J, Dawson MA, Maloney DG. Normal T, B, NK cell counts in healthy donors at 1 year after blood stem cell harvesting. Blood 2000; 95: 2993-2994.
8. Sakamaki S, Matsunaga T, Hirayama Y et al. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346: 1432-1433.
9. Anderlini P, Körbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903-908.
10. Hasenclever D, Sextro M. Safety of alloPBSCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17 (Suppl. 2): S28-S30.
11. Bortin MM, D'Amaro J, Bach FH et al. HLA associations with leukemia. Blood 1987; 70: 227-232.